Kura Oncology, Inc. (KURA): R&D Expense
$251.07M
Year ended 2025-12-31
$259.47M
Trailing 12 months to 2026-06-30
+39.3%
3-year compound annual growth
+33.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $251.07M | +47.7% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $169.97M | +47.5% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $115.23M | +24.2% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $92.81M | +9.6% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $84.72M | +40.3% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $60.40M | +26.3% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $47.83M | +2.2% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $46.79M | +77.0% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $26.43M | n/a | 2020-02-25, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $115.11M | +16.1% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $240.28M | +38.9% |
Compare KURA, SPRO, RMTI, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗